sellWeak cluster of 5
Jeremy Bender sold $179k of DAWN
CHIEF EXECUTIVE OFFICER at Day One Biopharmaceuticals, Inc.. 15,459 shares at an average of $11.60, traded Feb 17, 2026, filed Feb 18, 2026.
Warning score
37Value
$179k
15,459 shares
Holdings after
204,603
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +12Trade size$179k at market
- 0Share of holdings soldSold 7.0% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001863107-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 15, 2026 | MOption exercise Common Stock | +4,750 | - | - | 181,915 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +11,688 | - | - | 193,603 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +11,687 | - | - | 205,290 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +14,812 | - | - | 220,102 | Feb 18, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock | -15,459 | $11.60 | $179k | 204,603 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -4,750 | $0.00 | $0 | 14,250 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -11,688 | $0.00 | $0 | 81,816 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -11,687 | $0.00 | $0 | 128,565 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -14,812 | $0.00 | $0 | 222,188 | Feb 18, 2026 |
Related signals
Other insiders at Day One Biopharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Day One Biopharmaceuticals, Inc. | Charles N York II COO and CFO | $70k 6,065 shares | -2% | |
| 30Weak | Day One Biopharmaceuticals, Inc. | Michael Vasconcelles Head of Research and Dev. | $32k 2,728 shares | -38% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $74k 6,395 shares | -8% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $67k 5,814 shares | -9% | |
| 36Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $142k 15,894 shares | -8% | |
| 28Weak | Day One Biopharmaceuticals, Inc. | Charles N York II COO and CFO | $36k 4,062 shares | -1% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $39k 4,319 shares | -6% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $33k 3,726 shares | -7% | |
| 35Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $109k 16,058 shares | -9% | |
| 20Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $25k 3,766 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.